Introducing ‘Current Treatment Algorithms’

A new year brings a new series for Blood Cancer Journal, an open-access journal published by Springer Nature. January 2018 sees the launch of a new article type called ‘Current Treatment Algorithms’. In this blog, Dr Ayalew Tefferi and Dr S. Vincent Rajkumar introduce the concept of this new article type and discuss its relevance in the vast field of hematological cancers.

Blood Cancer Journal is proud to announce the launch of ‘Current Treatment Algorithms’, a new article type dedicated to providing clear, authoritative, concise treatment pathways for hematologic malignancies.

Physicians in practice need immediate point-of-care management references that are simple, up-to-date and succinctly presented in a one-page format – this is something that is somewhat lacking in the field of blood cancers. We strongly believe that Current Treatment Algorithms can address this need and help fill the existing void.

Current Treatment Algorithms provide specific recommendations for the management of hematologic malignancies

Articles in this series are written by leading experts in the field, and are free of commercial bias. Unlike some traditional practice guidelines and pathways which often provide a list of possible options for treatment, Current Treatment Algorithms will provide highly specific recommendations for the management of a hematologic malignancy, which have been derived from an expert appraisal of the available literature.

Current Treatment Algorithms will be concise and illustrative, with the recommended treatment strategy for each blood cancer discussed in this series, presented in a flowchart alongside a critical review of the treatment algorithm. This visual representation of the step-by-step pathway for the recommended practices should make it easier for practicing clinicians to grasp the current state-of-the-art treatment of hematologic cancers.

As one of the top journals in the field of hematologic malignancies, Blood Cancer Journal is committed to ensuring that this series will provide compelling value to the readership and serve as a readily available resource for hematologists and oncologists worldwide.

The first two articles in this series focus on myeloproliferative neoplasms, namely polycythemia vera (PV) and essential thrombocythemia (ET). Patients with PV or ET are mostly followed by internists, with majority of patients being managed by aspirin therapy with or without phlebotomy as needed. It is important to protect these patients from therapeutic adventures that might cause more detrimental harm than benefit. These issues are addressed in detail by the treatment guidelines. Please visit the Current Treatment Algorithms collection page for all algorithms published to date.

Submit your next manuscript to the Current Treatment Algorithms section

Potential authors who are recognized experts in the field and are interested in writing for this section are invited to send a brief proposal to the Editors-in-Chief of Blood Cancer Journal. Articles in this series should not have any involvement of medical writing companies, and authors should have no significant financial conflicts of interest in the relevant field.

View the latest posts on the On Medicine homepage